MedTrace Logo

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

NCT03991936 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-03-27

Study results available
· View outcomes & findings →

Summary

This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.

Conditions

  • Nail Psoriasis
  • Nail Diseases

Interventions

DRUG

Placebos

Normal saline intralesional injection

DRUG

Triamcinolone Acetonide 2.5 mg/mL

2.5 mg/mL intralesional injection

DRUG

Triamcinolone Acetonide 5.0 mg/mL

5.0 mg/mL intralesional injection

DRUG

Triamcinolone Acetonide 7.5 mg/mL

7.5 mg/mL intralesional injection

DRUG

Triamcinolone Acetonide 10 mg/mL

10 mg/mL intralesional injection

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Shari Lipner, MD, PhD · Weill Medical College of Cornell University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-11
Primary Completion
2023-03-29
Completion
2023-03-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03991936 on ClinicalTrials.gov